Published on Sunday March 01, 2020

Smooth Drug Development January and February 2020 News Release

January and February were very busy months for Smooth Drug Development team. 
  • Smooth Drug Development won a contract for bioequivalence study with Vardenafil.
  • Smooth was awarded with an agreement for PV regulatory intelligence in Russia.
  • We were awarded with a contract for data management and medical writing project for a phase Ib project in oncology.
  • We were awarded with a phase III study with Buserelin in endometriosis. 
  • Smooth signed a contract for data management and medical writing activities for a project with venetoclax.
  • Smooth Drug Development signed contracts for three bioequivalence trials with enalapril of different dosages.
  • We signed a contract with a global pharma for drug development strategy preparation and market entering.
The year start was very productive in meeting important milestones in our projects:
  • Nimesulide bioequivalence trial was initiated.
  • Patient recruitment for Inhalypt trial was completed.
  • Bioequivalence trial with Enalapril, 5 mg was initiated.
  • Last patient last visit was performed in AML study.
  • Sites in our flu vaccine trial were initiated.
  • Aphobazol phase I project was closed out. 
  • Our phase I site was initiated in Enalapril, 10 and 20 mg study.
  • Sertaconazole phase III project is being closed by Smooth Drug Development team.  
  • Smooth Drug Development client is going to present clinical trial data from our ongoing trial in AML at ASCO conference in Chicago.